Comera Life Sciences Holdings, Inc. announced that on January 29, 2024, William Wexler resigned from the Company?s board of directors effective immediately. As of the time of his resignation, Mr. Wexler did not serve on any committees of the board of directors and his resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. On January 29, 2024, the Company terminated the employment of Jeff Hackman, President and Director, Michael Campbell, Executive Vice President and Robert Mahoney, Chief Scientific Officer effective January 31, 2024.

Mr. Hackman resigned as a director of the Company and its subsidiaries and from all other positions with the Company and its affiliates effective upon the termination of his employment on January 31, 2024. Mr. Hackman did not serve on any committees of the board of directors and his resignation was not due to any disagreement with the Company on any matter relating to its operations, policies or practices. On January 30, 2024, the Company engaged Mr. Campbell as a consultant and appointed him to serve as the Company?s principal accounting officer effective immediately following the termination of his employment on January 31, 2024.